RecruitingPhase 2NCT07226050

CLF065 for Chronic Pouchitis

A Randomized, Placebo-Controlled Phase 2 Study to Evaluate the Safety and Efficacy of CLF065 in the Treatment of Chronic Pouchitis

Sponsor

Calibr, a division of Scripps Research

Enrollment

20 participants

Start Date

Jun 1, 2026

Study Type

INTERVENTIONAL

Conditions

Pouchitis

Summary

This clinical trial is to evaluate investigational compound CLF065 as a treatment for adult patients with chronic pouchitis. The goals are to establish the safety, feasibility and efficacy of weekly dosing of long acting CLF065 versus placebo.

Eligibility

Min Age: 18 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called CLF065 and a drug called Placebo for people with pouchitis. The study is currently recruiting participants at 3 locations. People eligible for this study include aged 18 Years to 80 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGCLF065

will receive investigational product every week for 13 weeks as a sub-cutaneous injection

DRUGPlacebo

CLF065 matching placebo

Locations(3)

Scripps Health

La Jolla, California, United States

Phillip Fleshner, M.D. Inc

Los Angeles, California, United States

Lenox Hill Hospital

New York, New York, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07226050

Related Trials

Fecal Microbiota Transplant for Patients With Chronic Pouchitis

NCT058291091 location

A Study to Learn About the Safety of Vedolizumab and How Well it Works in Children and Teenagers With Active Chronic Pouchitis

NCT0644350214 locations